KineMed, which develops biomarker tests to measure the progression of diseases, announced terms for its IPO on Monday. The Emeryville, CA-based company plans to raise $32 million by offering 4.5 million shares at a price range of $6.50 to $7.50. At the midpoint of the proposed range, KineMed would command a fully diluted market value of $121 million. KineMed, which was founded in 2001 and booked $7 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol KNMD.
Help employers find you! Check out all the jobs and post your resume.
